Analysis Group Team Publishes Study Reviewing Real-World Treatment Patterns and Survival of US Patients with Metastatic Castration-Resistant Prostate Cancer Prior to PARP Inhibitors
August 18, 2021
A new study reviewed treatment patterns in the US for metastatic castration-resistant prostate cancer (mCRPC) from 2013 to 2019, before the US Food and Drug Administration’s approval of polyadenosine-diphosphate-ribose polymerase inhibitors (PARPi) in 2020. The research team, which included Analysis Group Managing Principal Mei Sheng Duh, Vice President François Laliberté, Senior Research Professional Malena Mahendran, Associate Dominique Lejeune, and Senior Analyst Louise Yu, along with researchers from Carolina Urologic Research Center and Merck & Co., also assessed overall survival rates.
Within five years of a prostate cancer diagnosis, an estimated 10–20% of patients develop castration-resistant prostate cancer. mCRPC, the most advanced form of prostate cancer, is associated with a poor prognosis. The study authors aimed to fill a knowledge gap by assessing real-world data from the pre-PARPi era to benchmark the novel treatment’s expected impact. Among other findings, the authors noted that rapid progression through pre-PARPi lines of treatment was associated with an increased risk of death, indicating an unmet need for life-prolonging treatments.
“Taken together,” the authors write, “these findings highlight the aggressive nature of mCRPC and the need for more effective novel treatments that prolong survival among patients with mCRPC.”
The researchers drew from de-identified patient records in the US Flatiron Health Electronic Health Record-derived database, and used a retrospective longitudinal observational cohort design. The study, “Real-World Treatment Patterns and Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer in the US Prior to PARP Inhibitors,” was published in Advances in Therapy.